A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis

The purpose of this study is to learn more about whether AZD0120 is safe to administer to people with relapsed or refractory AL amyloidosis, those who haven't responded well to previous treatments. Relapsed means your AL amyloidosis has returned after a period of improvement. Refractory means your AL amyloidosis has not responded to treatment. We also want to see if AZD0120 can help treat this condition. This study will also help to better understand AL Amyloidosis and associated health problems.

Are you Eligible? (Inclusion Criteria)

• Age greater than 18 years old - ECOG performance status of 0 to 1 -One or more organs currently or historically impacted by AL amyloidosis